Neuroprotective mechanisms of puerarin in middle cerebral artery occlusion-induced brain infarction in rats by Chang, Yi et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
Journal of Biomedical Science
Open Access Research
Neuroprotective mechanisms of puerarin in middle cerebral artery 
occlusion-induced brain infarction in rats
Yi Chang1,2, Cheng-Ying Hsieh2, Zi-Aa Peng3, Ting-Lin Yen2, George Hsiao3, 
Duen-Suey Chou3, Chien-Ming Chen2 and Joen-Rong Sheu*2,3
Address: 1Department of Anesthesiology, Shin Kong Wu Ho-Su Memorial Hospital and School of Medicine, Fu-Jen Catholic University, Taipei, 
2Graduate Institute of Medical Sciences, Taipei Medical University, Taipei 110, Taiwan and 3Department of Pharmacology, Taipei Medical 
University, Taipei 110, Taiwan
Email: Yi Chang - m004003@ms.skh.org.tw; Cheng-Ying Hsieh - d102093001@tmu.edu.tw; Zi-Aa Peng - monkeydocker@yahoo.com.tw; Ting-
Lin Yen - tbprince2002@yahoo.com.tw; George Hsiao - geohsiao@tmu.edu.tw; Duen-Suey Chou - fird@tmu.edu.tw; Chien-
Ming Chen - chenjame@tmu.edu.tw; Joen-Rong Sheu* - sheujr@tmu.edu.tw
* Corresponding author    
Abstract
Puerarin, a major isoflavonoid derived from the Chinese medical herb Radix puerariae (kudzu root),
has been reported to be useful in the treatment of various cardiovascular diseases. In the present
study, we examined the detailed mechanisms underlying the inhibitory effects of puerarin on
inflammatory and apoptotic responses induced by middle cerebral artery occlusion (MCAO) in
rats. Treatment of puerarin (25 and 50 mg/kg; intraperitoneally) 10 min before MCAO dose-
dependently attenuated focal cerebral ischemia in rats. Administration of puerarin at 50 mg/kg,
showed marked reduction in infarct size compared with that of control rats. MCAO-induced focal
cerebral ischemia was associated with increases in hypoxia-inducible factor-1α (HIF-1α), inducible
nitric oxide synthase (iNOS), and active caspase-3 protein expressions as well as the mRNA
expression of tumor necrosis factor-α (TNF-α) in ischemic regions. These expressions were
markedly inhibited by the treatment of puerarin (50 mg/kg). In addition, puerarin (10~50 μM)
concentration-dependently inhibited respiratory bursts in human neutrophils stimulated by formyl-
Met-Leu-Phe. On the other hand, puerarin (20~500 μM) did not significantly inhibit the
thiobarbituric acid-reactive substance reaction in rat brain homogenates. An electron spin
resonance (ESR) method was conducted on the scavenging activity of puerarin on the free radicals
formed. Puerarin (200 and 500 μM) did not reduce the ESR signal intensity of hydroxyl radical
formation. In conclusion, we demonstrate that puerarin is a potent neuroprotective agent on
MCAO-induced focal cerebral ischemia in vivo. This effect may be mediated, at least in part, by the
inhibition of both HIF-1α and TNF-α activation, followed by the inhibition of inflammatory
responses (i.e., iNOS expression), apoptosis formation (active caspase-3), and neutrophil
activation, resulting in a reduction in the infarct volume in ischemia-reperfusion brain injury. Thus,
puerarin treatment may represent a novel approach to lowering the risk of or improving function
in ischemia-reperfusion brain injury-related disorders.
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Background
Puerarin (daidzein-8-C-glucoside), is the major isoflavo-
noid derived from the Chinese medical herb Radix puerar-
iae (kudzu root). In China, R. puerariae is known as Ge
Gen, and has been used as a traditional medicine for treat-
ing various diseases including cardiovascular disorders
[1]. Puerarin has been shown to be effective in treating
heart diseases such as angina and myocardial infarction
[2]. The protective mechanisms of puerarin, at least in
part, are related to its ability to increase superoxide dis-
mutase activity, decrease lipid peroxidation, and enhance
fibrinolysis [2,3]. Furthermore, puerarin can also increase
cerebral blood flow in dogs [4], and reduces cerebral and
spinal cord injury in ischemia-reperfusion rats and rabbits
[5,6]. Several studies have also revealed that puerarin pos-
sesses protective effects against cortical neuron and astro-
cyte damage induced by oxygen-glucose deprivation or
glutamate excitotoxicity in vitro [7].
Ischemic hypoxic brain injury often causes irreversible
brain damage. The cascade of events leading to neuronal
injury and death in ischemia includes the release of
cytokines and free radicals, and induction of inflamma-
tion, apoptosis, and excitotoxicity [8]. Reperfusion of
ischemic areas could exacerbate ischemic brain damage
through the generation of reactive oxygen species (ROS),
including superoxide anions (O2
•-), hydroxyl radicals
(OH￿), and nitric oxide (NO) [9]. Neutrophils are a
potential source of ROS when activated during inflamma-
tory responses [10]. When a tissue suffers from ischemia
and reperfusion, proinflammatory cytokines produced by
inflammatory cells can trigger adhesion and migration of
circulating neutrophils to endothelial cells and generation
of ROS that enhances neutrophil infiltration and results in
ischemic injury [11]. Furthermore, ROS also mediate a
mitochondrial signaling pathway that may lead to apop-
tosis followed by cerebral ischemia [12]. Various in vitro
studies have demonstrated that cellular or biochemical
signaling pathways involve mitochrondria-derived activa-
tor of caspases, activation of downstream caspase-9 and -
3, and DNA fragmentation [12]. Therefore, pharmacolog-
ical agents which reduce ROS formation have been found
to limit the extent of brain damage following stroke-like
events [13].
Recently, Xu et al. [7] demonstrated that puerarin (100
mg/kg) possesses neuroprotective effects against cerebral
ischemia in rats. However, the detailed mechanisms
underlying the neuroprotective effects of puerarin in
inflammatory and apoptotic responses induced by middle
cerebral artery occlusion (MCAO) have still not yet been
completely resolved. We therefore further examined the
effect of puerarin in MCAO-induced cerebral ischemia,
and utilized the findings to further characterize the neuro-
protective mechanisms of puerarin.
Methods
Materials
Puerarin, 2,3,5-triphenyltetrazolium (TTC), aprotinin,
cremophor EL, leupeptin, lucigenin, N-formyl-Met-Leu-
Phe (fMLP), and bovine serum albumin (BSA) were pur-
chased from Sigma (St. Louis, MO). Ficoll-Paque plus was
purchased from Amersham (Buckinghamshire, HP, UK).
Puerarin was dissolved in solvent (cremophor: ethanol:
normal saline at 1: 1: 4) for the in vivo studies, and dis-
solved in 0.5% DMSO for the in vitro studies.
MCAO-induced transient focal cerebral ischemia in rats
Male Wistar rats (250~300 g) were used in this study. All
animal experiments and care were performed according to
the Guide for the Care and Use of Laboratory Animals
(National Academy Press, Washington, DC, 1996). Before
undergoing the experimental procedures, all animals were
clinically normal, were free of apparent infection or
inflammation, and showed no neurological deficits.
Animals were anesthetized with a mixture of 75% air and
25% O2 gases containing 3% isoflurane. The rectal tem-
perature was maintained at 37 ± 0.5°C. The right middle
cerebral artery (MCA) was occluded as described in our
previous report [14]. Briefly, the right common carotid
artery was exposed, and a 4-0 monofilament nylon thread
(25 mm) coated with silicon was then inserted from the
external into the internal carotid artery until the tip
occluded the origin of the MCA. After closure of the oper-
ative sites, the animals were allowed to awake from the
anesthesia. During another brief period of anesthesia, the
filament was gently removed after 1 h of MCAO. An
observer blinded to the identity of the groups assessed the
neurological deficits at 1 and 24 h after reperfusion
(before euthanization) by the forelimb akinesia (also
called the postural tail-hang) test, whereas the spontane-
ous rotational test was used as a criterion for evaluating
the ischemic insult [15]. Animals not showing behavioral
deficits at the above time points after reperfusion were
excluded from the study. On the other hand, reperfusion
was also ensured by an improvement in ipsilateral local
blood flow to at least 60% of the baseline following an
initial sharp decrease to about 50–60% of the baseline
caused by MCAO as determined using a continuous laser
Doppler flowmeter (LDF; Oxford Array™, Oxford Optro-
nix, Oxford, UK) with a standard needle probe (pp-051).
For the continuous measurement of local regional cere-
bral blood flow (rCBF), the rat was fixed in a stereotaxic
frame. The skull was exposed, and a burr hole in a diame-
ter of 2 mm was drilled on the right side of the skull at 2
mm posterior and 5 mm lateral to the bregma to accom-
modate the probeholder. LDF was used to estimate blood
flow continuously during ischemia and reperfusion.
Rats were euthanized by decapitation after 24 h of reper-
fusion. The brains were cut into 2-mm coronal slices start-Journal of Biomedical Science 2009, 16:9 http://www.jbiomedsci.com/content/16/1/9
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ing 1 mm from the frontal pole. Each stained brain (2%
TTC) slice was drawn using a computerized image ana-
lyzer (Image-Pro plus). The calculated infarct areas were
then compiled to obtain the infarct volume (mm3) per
brain. Infarct volumes were expressed as a percentage of
the contralateral hemisphere volume using the formula:
(the area of the intact contralateral [left] hemisphere – the
area of the intact region of the ipsilateral [right] hemi-
sphere) to compensate for edema formation in the ipsilat-
eral hemisphere [14].
All animals were divided into four groups: (1) a sham-
operated group; (2) a solvent-treated (solvent) group (cre-
mophor: ethanol: normal saline at 1: 1: 4); and groups
treated with a single dose of (3) 25 or (4) 50 mg/kg, i.p.
of puerarin. In the group treated with the solvent or puer-
arin, rats were given the isovolumetric solvent or puerarin
(25 or 50 mg/kg) 10 min before MCAO.
Neurobehavioral test
The sensorimotor integrity was conducted to assess the
neurobehavior at 1 and 24 h after MCAO in rats [15]. Five
categories of motor neurological findings were scored: 0,
no observable deficit; 1, forelimb flexion; 2, forelimb flex-
ion and decreased resistance to lateral push; 3, forelimb
flexion, decreased resistance to lateral push and unilateral
circling; 4, forelimb flexion, unable or difficult to ambu-
late.
Determination of the expressions of HIF-1 , iNOS, and 
active caspase-3 in MCAO-insulted brain
The expressions of HIF-1α, iNOS, and active caspase-3 in
the brain at 24 h after MCAO-reperfusion injury were ana-
lyzed by Western blotting as described by Rodrigo et al.
[16] with minor modifications. The MCAO-insulted and
sham-operated rats were anesthetized with chloral
hydrate (400 mg/kg, i.p.), then the apex of the heart was
penetrated with a perfusion cannula inserted through the
left ventricle into the ascending aorta. Perfusion with ice-
cold phosphate-buffered saline (PBS) was performed, and
an incision was made in the right atrium for venous
drainge. Brains were removed freshly and sectioned coro-
nally into four sequential parts from the frontal lobe to
the occipital lobe. The third parts of the right hemisphere
was separately collected, snap-frozen in liquid nitrogen,
and stored at -70°C. The frozen tissues were placed in
homogenate buffer and homogenized, then sonicated for
10 s three times at 4°C. The sonicates were subjected to
centrifugation (10,000 g).
The supernatant (50 μg protein) was subjected to SDS-
PAGE and electrophoretically transferred to PVDF mem-
branes (0.45 μm; Hybond-P; Amersham). After incuba-
tion in blocking buffer and being washed three times with
TBST buffer (10 mM Tris-base, 100 mM NaCl, and 0.1%
Tween 20; pH 7.5), the blots were treated with an anti-
HIF-1α polyclonal antibody (pAb, 1: 1000; R&D, Minne-
apolis, MN), an anti-iNOS monoclonal antibody (mAb;
1: 3000, BD Biosciences, San Jose, CA), and an anti-active
caspase-3 pAb (1: 250; Biovision, Mountain View, CA), or
an anti-α-tubulin mAb (1: 2000; Santa Cruz Biotech,
Santa Cruz, CA) in TBST buffer overnight. Blots were sub-
sequently washed with TBST and incubated with second-
ary horseradish peroxidase-conjugated goat anti-mouse
mAb or donkey anti-rabbit IgG (Amersham) for 1 h. The
blots were then washed, and the immunoreactive protein
was detected using film exposed to enhanced chemilumi-
nescence detection reagents (ECL+ system; Amersham).
The bar graph depicts the ratios of quantitative results
obtained by scanning reactive bands and quantifying the
optical density using Videodensitometry (Bio-1D version
99 image software).
Isolation of total RNA and reverse-transcription 
polymerase chain reaction (RT-PCR)
Fresh brains were removed, separated into ipsilateral and
contralateral hemispheres, snap frozen in liquid nitrogen
and stored at -70°C until used as stated above. Total RNA
was isolated from the ipsilateral cortex by a commercially
available kit according to the manufacturer's instructions
(TRIzol, Gibco). For each RT-PCR, 0.5 mg of the RNA
sample and 0.2 μM of primers were reverse-transcribed
and amplified in a 50-μl reaction mixture of commercially
available reagents (SUPERSCRIPT One-Step RT-PCR with
PLATINUM Taq Kit, Invitrogen) containing a 1× reaction
mixture and 0.2 μM of an RT/Taq mixture in one cycle of
30 min at 50°C for reverse transcription and one cycle at
95°C for 3 min, followed by 40 cycles at 95, 62, and 72°C
for 30, 40, and 40 s, respectively; with a single extension
step at 72°C for 5 min followed by 4°C for amplification
in a thermal cycler (GeneAmp PCR system 2400, Perkin-
Elmer). For visualization and quantification by densitom-
etry of each RT-PCR, a 10-μl aliquot was subjected to elec-
trophoresis on a 1.5% agarose gel using a mini horizontal
submarine unit (HE 33) containing 0.5 mg/ml ethidium
bromide to allow UV-induced fluorescence (TCP-20.M,
Vilber Lourmat). Preliminary experiments were per-
formed to determine the range of amplification cycles and
the beginning RNA substrate within the linear phase of
the exponential increase of the PCR products for each par-
ticular primer pair.
Determination of respiratory bursts in human neutrophils
Superoxide anion production of neutrophils was meas-
ured by the method of lucigenin-enhanced chemilumi-
nescence (LCL) as described by Hsiao et al. [17] with some
modifications. Washed neutrophil suspensions (2 × 106
cells/ml) in modified Hank's balanced salt solution
(HBSS) containing 1 mM CaCl2 and 0.5 mM MgCl2 were
dispensed into wells of a standard scintillation micro-Journal of Biomedical Science 2009, 16:9 http://www.jbiomedsci.com/content/16/1/9
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plate. Before the assay, cells were preincubated with the
solvent control (0.5% DMSO) or various concentrations
of puerarin (10, 20, and 50 μM). Then, 20-μl aliquots of
lucigenin were added at a final concentration of 100 μM.
The basal LCL was recorded for 1 min by a microplate
luminometer (Orion®, Berthold, Germany) at 37°C, and
cells were immediately stimulated with fMLP (800 nM).
The luminescent light was continuously recorded for 5
min. The chemiluminescent signal was represented as rel-
ative light units per second (RLU/s). The results of LCL
intensity (as increments in the signal intensity) were
determined by measuring basal and stimulator-induced
peak values and calculating the difference between them.
Antioxidative activity of puerarin in rat brain homogenate 
preparations
Rat brain homogenates were prepared from brains of
freshly killed Wistar rats, and the peroxidation in the pres-
ence of iron ions was measured by the thiobarbituric acid
(TBA) method, as described by Braughler et al. [18] with
some modifications. In brief, whole brain tissue, exclud-
ing the cerebellum, was washed and homogenized in 10
volumes of ice-cold Krebs buffer. The homogenate was
centrifuged, and the supernatant was used immediately
for the lipid peroxidation assays. The reaction mixture
with puerarin or vehicle solution (0.5% DMSO) was incu-
bated for 10 min, then stimulated by the addition of fer-
rous ions (200 μM). The reactions were terminated by
adding a trichloroacetic acid solution and the TBA-reac-
tive substance (TBARS) reagent. After boiling for 15 min,
samples were cooled and extracted with n-1-butanol. The
extent of lipid peroxidation was estimated as TBARS and
was read at 532 nm in a spectrophotometer (Hitachi,
Model U3200). Tetramethoxypropane was used as a
standard, and the results were expressed as nanomoles of
malondialdehyde equivalents per milligram protein of
the supernatant of rat brain homogenates. The protein
contents of the brain homogenates and other prepara-
tions were determined with the Bio-Rad method.
Electron spin resonance (ESR) spectrometry
ESR spectra were recorded on a Bruker EMX ESR spectrom-
eter in the H2O2/NaOH/DMSO system as described previ-
ously [13]. Briefly, 100 μl of DMSO and the same volumes
of 25 mM NaOH and puerarin (200 and 500 μM) were
mixed in a test tube, followed by the addition of 10 μl
DMPO and 100 μl of 30% H2O2. The reaction mixture
was aspirated into a quartz flat cell and set in the ESR
apparatus; scanning was begun 1 min after all reagents
were mixed. The rate of free radical-scavenging activity
was defined by the following equation: inhibition rate =
1-[signal height (puerarin)/signal height (solvent con-
trol)] [13].
Statistical analysis
The experimental results are expressed as the means ±
S.E.M. and are accompanied by the number of observa-
tions. Student's unpaired t-test was used to determine sig-
nificant differences in the study of MCAO-induced
cerebral ischemia. The other experiments were assessed by
the method of analysis of variance (ANOVA). If this anal-
ysis indicated significant differences among the group
means, then each group was compared using the New-
man-Keuls method. A P value of < 0.05 was considered
statistically significant.
Results
Effect of puerarin on MCAO-induced focal cerebral 
ischemia in rats
All animals in this study showed similar physiological val-
ues (i.e., rectal temperature and mean arterial blood pres-
sure) before, during, and after MCAO among groups (data
not shown). Neither abnormal behavior, depression of
respiration, nor hypothermia was observed in the solvent-
or puerarin-treated groups. The cerebral infarction was
examined using 2-mm-thick slices of the cerebrum 24 h
after MCAO reperfusion in rats through TTC staining. Fig-
ure 1A shows typical photographs of coronal sections of
the sham-operated, solvent (cremophor: ethanol: normal
saline at 1: 1: 4)-treated, and puerarin-treated groups (25
and 50 mg/kg) prior to the ischemic insult. Administra-
tion of puerarin at 25 and 50 mg/kg showed dose-depend-
ent reductions in infarct volume (white area) compared to
the solvent-treated group (solvent, 37.7 ± 2.6% vs. 25 mg/
kg, 32.8 ± 1.9%; 50 mg/kg, 14.9 ± 2.0%, n = 5) (Fig. 1B).
On the other hand, treatment with the solvent did not sig-
nificantly influence the infarct size compared with the
MCAO group (without treatment with solvent or drugs)
(data not shown). Figure 1C gives statistical results of the
infarct areas of solvent- and puerarin (50 mg/kg)-treated
groups at various distances from the frontal pole. The inf-
arct area was largest between the 3rd and 4th sections in
both groups. Treatment with puerarin (50 mg/kg) mark-
edly reduced the infarct area in all regions, especially in
sections three to five (Fig. 1C). In addition, the relative
changes of regional cerebral blood flow (rCBF) were
recorded using LDF during MCAO-reperfusion periods. In
all groups, MCAO induced a similar immediate reduction
of rCBF to approximately 50–60% of the baseline level.
The rCBF value of puerarin (50 mg/kg)-treated group was
not significantly influenced as compared to the solvent-
treated group at the 10 min after MCAO (solvent-treated
group, 95.9 ± 8.5% vs. puerarin-treated group, 105.7 ±
9.7%, P > 0.05; n = 6) (Fig. 2A). This result may indicate
that the neuroprotective effect of puerarin in MCAO-
induced cerebral ischemia could not relate to its ability to
increase rCBF. In addition, an obvious improvement was
observed in neurological function of puerarin (50 mg/Journal of Biomedical Science 2009, 16:9 http://www.jbiomedsci.com/content/16/1/9
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Effect of puerarin in middle cerebral artery occlusion (MCAO)-induced focal cerebral ischemia in rats Figure 1
Effect of puerarin in middle cerebral artery occlusion (MCAO)-induced focal cerebral ischemia in rats. (A) 
Coronal sections of TTC-stained brains, (B) dose-response effect of puerarin, and (C) infarct area at various distances from the 
frontal pole in 24 h after MACO-reperfusion rats. Cerebral infarction in sham-operated (sham) or MACO-reperfusion rats is 
from a representative animal that received solvent (solvent; cremophor: ethanol: normal saline at 1: 1: 4) or puerarin (25 and 
50 mg/kg) intraperitoneally. (B) Infarct volumes were calculated as described in "Methods", and data are presented as a super-
imposed scatterplot showing the infarct volume for each animal in the group as well as the means ± S.E.M. (n = 5). ***P < 0.001 
compared to the sham-operated group; ###P < 0.001 compared to the solvent-treated group. (C) Forebrain profiles of the inf-
arct area at various distances from the frontal pole as described in "Methods". Each point (m, solvent-treated group; n, puer-
arin 50 mg/kg-treated group) and vertical bar represent the means ± S.E.M. (n = 5). *P < 0.05, **P < 0.01, and ***P < 0.001 
compared to the solvent-treated group.
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kg)-treated rats at 24 h after MCAO than that of solvent-
treated group (Fig. 2B).
Effects of puerarin on HIF-1 , iNOS, and active caspase-3 
protein expressions in ischemic cerebral tissues
Results of Western blotting of MCAO-insulted cerebral tis-
sues are shown in Figures 3 and 4. As shown in Figure 3A,
HIF-1α, detected as a major band of approximately 120
kDa 24 h after MCAO-reperfusion injury (lane 2) was
more pronounced than that of levels obtained in the cor-
responding area of the sham-operated group (lane 1).
Puerarin (50 mg/kg) treatment significantly (P < 0.05)
suppressed the expression of HIF-1α in ischemic cerebral
tissues (Fig. 3A, lane 3). In Figure 3B, the iNOS band,
detected as a major band of approximately 135 kDa,
showed significant increases in ischemic cerebral tissues
24 h after MCAO-reperfusion compared to that of sham-
operated rats. With administration of puerarin (50 mg/
kg), iNOS expression was markedly reduced in MCAO-
reperfusion rats (Fig. 3B).
In addition, negative immunostaining was obtained for
active caspase-3 in the sham-operated group (Fig. 4A, lane
1). At 24 h after MCAO-reperfusion, strong staining of
active caspase-3 (17 kDa) was observed in ischemic cere-
bral tissues (lane 2) compared to levels obtained in the
corresponding area of the sham-operated group (lane 1).
Again, puerarin (50 mg/kg) abolished the elevation of
active caspase-3 (Fig. 4A, lane 3).
Effect of puerarin on TNF-  mRNA expression in ischemic 
cerebral tissues
Transient MCAO resulted in a significant and more-sus-
tained increase in the expression of TNF-α mRNA in the
injured hemisphere compared to levels obtained in the
corresponding area of the sham-operated group (Fig. 4B).
Puerarin (50 mg/kg) treatment markedly reduced this
reaction (Fig. 5).
Effects of puerarin on respiratory bursts in human 
neutrophils and lipid peroxidation in rat brain 
homogenates
The inhibitory effect of puerarin on neutrophil activation
was evaluated by fMLP-induced lucigenin-dependent
chemiluminescence (LCL), which is an index of respira-
tory bursts, as produced by superoxide anions. When
human neutrophils (2 × 106 cells/ml) were treated with
fMLP (800 nM), a rapid generation of superoxide anions
was observed with the LCL signal. Puerarin (10~50 μM)
inhibited the increase in chemiluminescence stimulated
by fMLP in a concentration-dependent manner (Fig. 5A).
At 50 μM, puerarin greatly reduced the LCL stimulated by
fMLP to about 90% compared to the solvent control
(0.5% DMSO).
In addition, puerarin was further tested for its ability to
inhibit non-enzymatic lipid peroxidation in rat brain
homogenates stimulated by ferrous ions. At 20~500 μM,
puerarin did not significantly inhibit ferrous ions-induced
lipid peroxidation in rat brain homogenates (Fig. 5B). In
addition, puerarin (500 μM) did not interfere with the
TBA test, since color formation did not change if it was
added after incubation with TBA reagents. On the other
hand, α-tocopherol (200 μM) inhibited ion-dependent
lipid peroxidation in this reaction (data not shown).
Free radical-scavenging activity of puerarin
In this study, typical ESR signals of hydroxyl radicals were
observed as shown in Figure 6. Puerarin (200 and 500
μM) did not significantly suppress hydroxyl radical for-
mation as compared to the solvent-treated group. This
observation provides in vitro evidence suggesting the neu-
roprotective effect of puerarin did not mediate by the free
radical-scavenging activity.
Discussion
The present study demonstrates that MCAO-reperfusion
injury induces HIF-1α, iNOS, and active caspase-3 protein
expressions, and TNF-α mRNA expression, which may
represent the response of neurons suffering from ischemic
insult. Animal models of focal cerebral ischemia, for
which MCAO is usually used, reproduce the pattern of
ischemic brain damage observed in many human
ischemic stroke patients [19].
The increased HIF-1α protein level observed after MCAO-
reperfusion is presumably induced by a loss of the oxygen
supply [20], resulting in a greater extent of binding activity
to the iNOS gene and reaching a consequent peak of iNOS
protein expression. Since the iNOS gene contains the
hypoxia-responsive enhancer (HRE) sequence to which
HIF-1α binds [21], results from primary neuronal cultures
of cells demonstrated that HIF-1α binds to the iNOS pro-
moter gene under hypoxic conditions. Such binding is
associated with an increase in iNOS expression [22]. Fur-
thermore, HIF-1α combining with p53 may promote
apoptotic cell death in ischemic areas [23]. In addition,
the increased expression of iNOS may also contribute to
enhanced neuronal injury, since iNOS knock-out mice
show reduced brain damage after ischemia [24].
Several apoptosis-related proteins, including caspase-9
and -3, were all strongly expressed after ischemic injury. In
addition, hypoxia may cause HIF-1α to bind to p53 in
order to stabilize it, and also activates the expression of
various genes including Bax (a proapoptotic member of
the Bcl-2 family) [25]. Bax is translocated to the mito-
chondria where it releases cytochrome c into the cytosol
to interact with Apaf-1 to activate caspase-9, which in turn
activates downstream caspases, such as active caspase-3Journal of Biomedical Science 2009, 16:9 http://www.jbiomedsci.com/content/16/1/9
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Effect of puerarin in middle cerebral artery occlusion (MCAO)-induced regional cerebral blood flow (rCBF) and neurobehavio- ral deficits in rats Figure 2
Effect of puerarin in middle cerebral artery occlusion (MCAO)-induced regional cerebral blood flow (rCBF) 
and neurobehavioral deficits in rats. (A) rCBF of solvent- and puerarin (50 mg/kg)-treated rats were measured by laser 
Doppler flowmeter in the MCA-supplied cortex. The value of rCBF were recorded every 10 min after MCAO and reperfusion 
periods. Each point (m, solvent-treated group; n, puerarin 50 mg/kg-treated group) and vertical bar represent the means ± 
S.E.M. (n = 6). (B) Neurobehavioral scores of solvent- and puerarin (50 mg/kg)-treated rats were recorded at 1 and 24 h after 
MCAO. Each point (m, solvent-treated group; n, puerarin 50 mg/kg-treated group) and vertical bar represent the means ± 
S.E.M. (n = 5).
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Effects of puerarin on the expressions of (A) hypoxia-inducible factor-1α (HIF-1α) and (B) inducible nitric oxide synthase  (iNOS) in cerebral homogenates 24 h after middle cerebral artery occlusion (MCAO)-reperfusion injury in rats Figure 3
Effects of puerarin on the expressions of (A) hypoxia-inducible factor-1α (HIF-1α) and (B) inducible nitric 
oxide synthase (iNOS) in cerebral homogenates 24 h after middle cerebral artery occlusion (MCAO)-reper-
fusion injury in rats. Fresh brains from sham-operated (lane 1), solvent-treated (lane 2), and puerarin (50 mg/kg)-treated 
(lane 3) rats were removed and sectioned coronally into four sequential parts from the frontal lobe to the occipital lobe. The 
third part of the four sequential parts of the ischemic-injured hemisphere was separately collected, homogenized, and centri-
fuged. The supernatant (50 μg protein) was then subjected to SDS-PAGE, and transferred onto membranes for analysis of HIF-
1α and iNOS expressions. The results are representative examples of three similar experiments. Data are presented as the 
means ± S.E.M. **P < 0.01 compared to the sham-operated group (lane 1); #P < 0.05 and ##P < 0.01 compared to the solvent-
treated group (lane 2). Equal loading in each lane is demonstrated by similar intensities of α-tubulin.
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Effects of puerarin on the expressions of (A) active caspase-3 protein and (B) tumor necrosis factor (TNF)-α mRNA in cere- bral homogenates 24 h after middle cerebral artery occlusion (MCAO)-reperfusion injury in rats Figure 4
Effects of puerarin on the expressions of (A) active caspase-3 protein and (B) tumor necrosis factor (TNF)-α 
mRNA in cerebral homogenates 24 h after middle cerebral artery occlusion (MCAO)-reperfusion injury in 
rats. (A) Fresh brains from sham-operated, solvent-treated, and puerarin (50 mg/kg)-treated rats were removed, and sec-
tioned coronally into four sequential parts from the frontal lobe to the occipital lobe. The third part of the four sequential 
parts of the ischemic-injured hemisphere was separately collected, homogenized, and centrifuged. The supernatant (50 μg pro-
tein) was then subjected to SDS-PAGE, and transferred onto membranes for analysis of active caspase-3 expression. The 
results are representative examples of three similar experiments. Data are presented as the means ± S.E.M. *P < 0.05 com-
pared to the sham-operated group (lane 1); #P < 0.05 compared to the solvent-treated groups (lane 2). Equal loading in each 
lane is demonstrated by similar intensities of α-tubulin. (B) Fresh brains from sham-operated, solvent-treated, and puerarin (50 
mg/kg)-treated rats were removed, homogenized, and centrifuged from the ipsilateral cortex, followed by analysis of TNF-α 
mRNA expression by RT-PCR as described in "Methods". The GAPDH level was used to normalize the amount of the cDNA 
template used in each PCR reaction. The results are representative examples of three similar experiments.
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Effects of puerarin on (A) respiratory bursts in human neutrophils, and (B) the antioxidation in thiobarbituric acid-reactive sub- stance (TBARS) in rat brain homogenate Figure 5
Effects of puerarin on (A) respiratory bursts in human neutrophils, and (B) the antioxidation in thiobarbituric 
acid-reactive substance (TBARS) in rat brain homogenate. (A) Washed neutrophil suspensions (2 × 106 cells/ml) were 
preincubated with the solvent control (0.5% DMSO) or various concentrations of puerarin (10, 20, and 50 μM) in the presence 
of lucigenin (100 μM), followed by the addition of fMLP (800 nM) to trigger neutrophil respiratory bursts. Data are presented 
as a percent inhibition of the solvent control (means ± S.E.M., n = 4). (B) Brain homogenates were preincubated with solvent 
(0.5% DMSO) or various concentrations of puerarin (20~500 μM) for 10 min followed by the addition of Fe2+ (200 μM). 
Results are presented as the absorbance at 532 nm/mg protein in brain homogenates. Data are presented as the means ± 
S.E.M. (n = 4). **P < 0.01 compared with the solvent group (DMSO only).
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[26]. In the present study, we showed that elevations of
active caspase-3 and iNOS expressions occurred in the
same time frame as HIF-1α expression after ischemic
injury, and these expressions could be significantly sup-
pressed by puerarin. In addition, TNF-α is one of the key
immunomodulatory and proinflammatory cytokines
upregulated during brain ischemia [27]. Administration
of TNF-α during ischemic brain insult has been shown to
augment the injury, as evidenced by increased tissue dam-
age and neurological deficits [27]. In addition to inflam-
mation, TNF-α has also been shown to be involved in
apoptosis [28]. In this study, we also demonstrated that
puerarin can downregulate the transcription of TNF-α
during brain ischemia. Therefore, inhibition of active cas-
pase-3 expression by puerarin may occur, at least partially,
through the inhibition of TNF-α expression in ischemic
brain injury.
Leukocytes, particularly neutrophils, contribute to the ini-
tiation of ischemic stroke. Thus, infiltration of neutrophils
into the infarct areas following cerebral ischemia-reper-
fusion injury also plays a crucial role in the development
of cerebral infarction and neuronal damage [11].
Although neutrophils produce and release a variety of
toxic agents designed to kill microbes, those systems that
depend on reactive products of oxygen metabolism are
especially potent. These agents are produced as a conse-
quence of respiratory bursts, a series of events triggered by
phagocytosis or exposure to certain inflammatory media-
tors and feature a dramatic increase in oxidative metabo-
lism with direct conversion of molecular oxygen to its
univalent reduction product, the superoxide anion. Our
results showed that puerarin significantly inhibited neu-
trophil respiratory bursts by the chemotactic tripeptide,
fMLP, which can activate leukocytes, resulting in leuko-
cyte adhesion to the endothelium, leukocyte aggregation,
Effect of puerarin on the free radical-scavenging activity in the H2O2/NaOH/DMSO system Figure 6
Effect of puerarin on the free radical-scavenging activity in the H2O2/NaOH/DMSO system. The signal of hydroxyl 
radical peaks was observed in electron spin resonance (ESR) experiments. (A) Typical ESR spectra in the presence of solvent 
control (0.5% DMSO) or puerarin (B, 200 μM), (C, 500 μM) in the H2O2/NaOH/DMSO system, the spectrum is a representa-
tive example of four similar experiments.
A
B
CJournal of Biomedical Science 2009, 16:9 http://www.jbiomedsci.com/content/16/1/9
Page 12 of 13
(page number not for citation purposes)
decreased leukocyte deformability, and the release of oxi-
dants, proteases, and lipid metabolites [29].
The phospholipid bilayers of cellular and subcellular
membranes are undoubtedly major targets for free radi-
cals. The compound that inhibits membrane phospholi-
pid peroxidation seems to exert a pharmacological effect
in preventing radical-induced oxidative pathological
events. Among cell-free systems, brain homogenates are
usually chosen to evaluate an antioxidant's effect on lipid
peroxidation [18]. Rat brain homogenates exposed to fer-
rous ions exhibit lipid peroxidation in air by a mechanism
whose induction step may primarily involve site-bound,
iron-mediated decomposition of lipid hydroperoxides to
yield alkoxy or peroxyl radicals, leading to the chain reac-
tion of lipid peroxidation [30]. In this system, puerarin
did not effectively inhibit lipid peroxidation, indicating
that the inhibition of lipid peroxidation might not be the
neuroprotective mechanism of puerarin in ischemic brain
injury.
In conclusion, the most important findings of this study
suggest that the neuroprotective effect of puerarin on cer-
ebral ischemic damage in MCAO-reperfusion rats is prob-
ably mediated by the inhibition of HIF-1α and TNF-α,
followed by the inhibition of inflammatory responses
(i.e., iNOS), apoptosis (active caspase-3), and neutrophil
activation. Puerarin itself possesses neither free radical-
scavenging nor antioxidative activity, whereas it may
reduce superoxide anion formation probably through
inhibiting neutrophil activation. The rationale for the use
of puerarin is based on the fact that multiple deleterious
processes in different cell types of organelles are initiated
during ischemia-reperfusion injury which ultimately syn-
ergistically moves toward irreversible injury. Therefore,
treatment using puerarin is not limited to one factor but
involves many mechanisms, most of which may be inter-
related. For example, puerarin-induced neuroprotection is
related to inflammation, NO, and apoptosis, and many of
those factors (such as iNOS, active caspase-3, etc) are
related to HIF-1α. We speculate that the correction of
these molecules and morphological changes may lead to
neurobehavioral improvement in patients; thus, treat-
ment using puerarin may represent an ideal approach for
improving function after ischemia-reperfusion brain
injury.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
YC, CYH, and ZAP carried out the animal study. YC, TLY,
and GH participated in the Western blotting assays. GH
carried out the neutrophil study. DSC and CMC carried
out the ESR study. YC and CYH participated in the design
of the study and performed the statistical analysis. JRS
conceived of the study, participated in its design and coor-
dination, and collectively prepared the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported by grants from the National Science Council of 
Taiwan (NSC95-2314-B-038-016-MY2); the Committee on Chinese Medi-
cine and Pharmacy (CCMP95-RD-012); and Shin Kong Wu Ho-Su Memorial 
Hospital (SKH-TMU-95-05; SKH-8302-95-DR-31).
References
1. Yeung DKY, Leung SWS, Xu YC, Vanhoutte PM, Man RY: Puerarin,
an isoflavonoid derived from Radix puerariae, potentiates
endothelium-independent relaxation via the cyclic AMP
pathway in porcine coronary artery.  Eur J Pharmacol 2006,
552:105-111.
2. Gao Q, Yang B, Ye ZG, Wang J, Bruce IC, Xia Q: Opening the cal-
cium-activated potassium channel participates in the cardio-
protective effect of puerarin.  Eur J Pharmacol 2007, 574:179-184.
3. Chen J, Xu J, Li J: Effect of puerarin on fibrinolytic activity and
lipid peroxide in patients with coronary heart disease.  Zhong-
guo Zhong Xi Yi Jie He Za Zhi 1999, 19:649-650.
4. Chen L, Chai Q, Zhao A, Chai X: Effect of puerarin on cerebral
blood flow in dogs.  Chin Material Med J 1995, 20:560-562.
5. Wang L, Zhao A, Wang F, Chai Q, Chai X: Protective effect of
puerarin on acute cerebral ischemia in rats.  Chin Material Med
J 1997, 22:752-754.
6. Sang HF, Zhang YM, Xu LX, Wang Q, Ji GL, Wu MC: Protective
e f f e c t  o f  p u e r a r i n  o n  s p i n a l  cord injury resulting from
ischemia and reperfusion in rabbits.  Fourth Mil Med Univ J 2001,
22:414-417.
7. Xu X, Zhang S, Zhang L, Yan W, Zheng X: The neuroprotection
of puerarin against cerebral ischemia is associated with the
prevention of apoptosis in rats.  Planta Med 2005, 71:585-591.
8. Kuroda S, Siesjo BK: Reperfusion damage following focal
ischemia: pathophysiology and therapeutic windows.  Clin
Neurosci 1997, 4:199-212.
9. Iadecola C, Zhang F, Casey R, Clark HB, Ross ME: Inducible nitric
oxide synthase gene expression in vascular cells after tran-
sient focal cerebral ischemia.  Stroke 1996, 27:1373-1380.
10. Lipton P: Ischemic cell death in brain neurons.  Physiol Rev 1999,
79:1431-1568.
11. Liou KT, Shen YC, Chen CF, Tsao CM, Tsai SK: Honokiol protects
rat brain from focal cerebral ischemia-reperfusion injury by
inhibiting neutrophil infiltration and reactive oxygen species
production.  Brain Res 2003, 992:159-166.
12. Chan PH: Reactive oxygen radicals in signaling and damage in
the ischemic brain.  J Cereb Blood Flow Metab 2004, 21:2-14.
13. Hsiao G, Lee JJ, Chen YC, Lin JH, Shen MY, Lin KH, Chou DS, Sheu
JR: Neuroprotective effects of PMC, a potent α-tocopherol
derivative, in brain ischemia-reperfusion: reduced neu-
trophil activation and anti-oxidant actions.  Biochem Pharmacol
2007, 73:382-393.
14. Hsiao G, Lin KH, Chang Y, Chen TL, Tzu NH, Chou DS, Sheu JR: Pro-
tective mechanisms of inosine in platelet activation and cer-
ebral ischemic damage.  Arterioscler Thromb Vasc Biol 2005,
25:1998-2004.
15. Lee EJ, Chen HY, Wu TS, Chen TY, Ayoub IA, Maynard KI: Acute
administration of Ginkgo biloba extract (EGb 761) affords
neuroprotection against permanent and transient focal cer-
ebral ischemia in Sprague-Dawley rats.  J Neurosci Res 2002,
68:636-645.
16. Rodrigo J, Alonso D, Fernandez AP, Serrano J, Richart A, López JC,
Santacana M, Martínez-Murillo R, Bentura ML, Ghiglione M, Uttenthal
LO: Neuronal and inducible nitric oxide synthase expression
and protein nitration in rat cerebellum after oxygen and glu-
cose deprivation.  Brain Res 2001, 909:20-45.
17. Hsiao G, Teng CM, Sheu JR, Cheng YW, Lam KK, Lee YM, Wu TS,
Yen MH: Cinnamophilin as a novel antiperoxidative cytopro-
tectant and free radical scavenger.  Biochim Biophys Acta 2001,
1525:77-88.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Biomedical Science 2009, 16:9 http://www.jbiomedsci.com/content/16/1/9
Page 13 of 13
(page number not for citation purposes)
18. Braughler JM, Burton PS, Chase RL, Pregenzer JF, Jacobsen EJ, Van-
Doornik FJ, Tustin JM, Ayer DE, Bundy GL: Novel membrane
localized iron chelators as inhibitors of iron-dependent lipid
peroxidation.  Biochem Pharmacol 1988, 37:3853-3860.
19. Ginsberg MD, Busto R: Rodent models of cerebral ischemia.
Stroke 1989, 20:1627-1642.
20. Wiener CM, Booth G, Semenza GL: In vivo expression of mRNAs
encoding hypoxia-inducible factor 1.  Biochem Biophys Res Com-
mun 1996, 225:485-488.
21. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio L: A
hypoxia-responsive element mediates a novel pathway of
activation of the inducible nitric oxide synthase promoter.  J
Exp Med 1995, 182:1683-1693.
22. Moro AM, De Alba J, Leza JC, Lorenzo P, Fernández AP, Bentura ML,
Boscá L, Rodrigo J, Lizasoain I: Neuronal expression of inducible
nitric oxide synthase after oxygen and glucose deprivation in
rat forebrain slices.  Eur J Neurosci 1998, 10:445-456.
23. Matrone C, Pignataro G, Molinaro P, Irace C, Scorziello A, Di Renzo
GF, Annunziato L: HIF-1α reveals a binding activity to the pro-
moter of iNOS gene after permanent middle cerebral artery
occlusion.  Neurochem 2004, 90:368-378.
24. Iadecola C, Zhang F, Casey R, Nagayama M, Ross ME: Delayed
reduction of ischemia brain injury and neurological deficits in
mice lacking the nitric oxide synthase gene.  J Neurosci 1997,
17:9157-9164.
25. Gibson ME, Han BH, Choi J, Knudson CM, Korsmeyer SJ, Parsadanian
M, Holtzman DM: BAX contributes to apoptotic-like death fol-
lowing neonatal hypoxia-ischemia: evidence for distinct
apoptosis pathways.  Mol Med 2001, 7:644-655.
26. Suzuki H, Tomida A, Tsuruo T: Dephosphorylated hypoxia-
inducible factor 1 alpha as a mediator of p53-dependent
apoptosis during hypoxia.  Oncogene 2001, 20:5779-5788.
27. Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN,
Lysko PG, Feuerstein GZ: Tumour necrosis factor α. A media-
tor of focal ischemic brain injury.  Stroke 1997, 28:1233-1244.
28. Gupta S: Molecular steps of tumor necrosis factor receptor-
mediated apoptosis.  Curr Mol Med 2001, 1:317-324.
29. Kochanek PM, Hallenbeck JM: Polymorphonuclear leukocytes
and monocytes/macrophages in the pathogenesis of cerebral
ischemia and stroke.  Stroke 1992, 23:1367-1379.
30. Braughler JM, Chase RL, Pregenzer JF: Oxidation of ferrous iron
during peroxidation of lipid substrates.  Biochim Biophys Acta
1987, 921:457-464.